September 18, 2013 | By Carly Helfand
There's no doubt the pharma bribery scandal has been bad for business in China. Just how bad? That remains to be seen. But in the meantime, Reuters reports that drugmakers are struggling to push their products--and explores how those problems might affect third-quarter results.
Read more: Pharma suffers in China as widening scandal spooks docs, reps - FiercePharma http://www.fiercepharma.com/story/pharma-suffers-china-widening-scandal-spooks-docs-reps/2013-09-18#ixzz2fHobZ0VD
Subscribe at FiercePharma
Read more: Pharma suffers in China as widening scandal spooks docs, reps - FiercePharma http://www.fiercepharma.com/story/pharma-suffers-china-widening-scandal-spooks-docs-reps/2013-09-18#ixzz2fHobZ0VD
Subscribe at FiercePharma
No comments:
Post a Comment